TNSN07385A1 - Therapeutic combination in case of benign prostate hyperplasia - Google Patents

Therapeutic combination in case of benign prostate hyperplasia

Info

Publication number
TNSN07385A1
TNSN07385A1 TNP2007000385A TNSN07385A TNSN07385A1 TN SN07385 A1 TNSN07385 A1 TN SN07385A1 TN P2007000385 A TNP2007000385 A TN P2007000385A TN SN07385 A TNSN07385 A TN SN07385A TN SN07385 A1 TNSN07385 A1 TN SN07385A1
Authority
TN
Tunisia
Prior art keywords
benign prostate
prostate hyperplasia
case
therapeutic combination
inhibitor
Prior art date
Application number
TNP2007000385A
Other languages
English (en)
Inventor
Helmut Haning
Peter Serno
Erwin Bischoff
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of TNSN07385A1 publication Critical patent/TNSN07385A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TNP2007000385A 2005-04-13 2007-10-11 Therapeutic combination in case of benign prostate hyperplasia TNSN07385A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005016981A DE102005016981A1 (de) 2005-04-13 2005-04-13 Kombination zur Therapie bei benigner Prostatahyperplasie
PCT/EP2006/002941 WO2006108519A1 (fr) 2005-04-13 2006-03-31 Combinaison pour traiter une hyperplasie benigne de la prostate

Publications (1)

Publication Number Publication Date
TNSN07385A1 true TNSN07385A1 (en) 2009-03-17

Family

ID=36608700

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2007000385A TNSN07385A1 (en) 2005-04-13 2007-10-11 Therapeutic combination in case of benign prostate hyperplasia

Country Status (22)

Country Link
EP (1) EP1888075A1 (fr)
JP (1) JP2008535877A (fr)
KR (1) KR20080007252A (fr)
CN (1) CN101193638A (fr)
AR (1) AR053575A1 (fr)
AU (1) AU2006233567A1 (fr)
BR (1) BRPI0610634A2 (fr)
CA (1) CA2605224A1 (fr)
CR (1) CR9427A (fr)
DE (1) DE102005016981A1 (fr)
DO (1) DOP2006000074A (fr)
GT (1) GT200600145A (fr)
IL (1) IL186604A0 (fr)
MA (1) MA29683B1 (fr)
MX (1) MX2007012567A (fr)
PE (1) PE20061338A1 (fr)
RU (1) RU2007141518A (fr)
SV (1) SV2008002477A (fr)
TN (1) TNSN07385A1 (fr)
TW (1) TW200716122A (fr)
UY (1) UY29473A1 (fr)
WO (1) WO2006108519A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
WO2007047282A1 (fr) * 2005-10-12 2007-04-26 Lilly Icos Llc Traitement d'une hypertrophie benigne de la prostate et de symptomes dans les voies urinaires inferieures
CA2633570A1 (fr) * 2005-12-21 2007-06-28 Pfizer Products Inc. Combinaison pharmaceutique d'un inhibiteur de pde-5 et d'un inhibiteur de 5-alpha reductase
MX2008016569A (es) * 2006-07-07 2009-01-30 Teva Pharma Composiciones solidas que contienen tadalafil y al menos un portador.
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
PL2222300T3 (pl) 2007-12-13 2015-02-27 Vanda Pharmaceuticals Inc Sposób i skład preparatu do leczenia chorób z udziałem receptorów serotoniny
CA2709103C (fr) 2007-12-13 2017-01-17 Vanda Pharmaceuticals Inc. Procede et composition pour traiter une affection vehiculee par alpha-adrenocepteur
US8885621B2 (en) 2010-04-26 2014-11-11 Intel Corporation Method, apparatus and system for switching traffic streams among multiple bands
WO2013123965A1 (fr) * 2012-02-20 2013-08-29 Synthon Bv Formulation pharmaceutique à dose fixe
CN102727456B (zh) * 2012-07-03 2016-06-22 北京科信必成医药科技发展有限公司 药物口腔崩解片及其制备方法
RU2672573C2 (ru) * 2013-06-28 2018-11-16 Ханми Фарм. Ко., Лтд. Фармацевтический комбинированный состав капсулы, содержащий тадалафил и тамсулозин
KR20240015735A (ko) 2013-07-23 2024-02-05 세레니티 파마슈티컬즈 엘엘씨 베타-3-아드레날린 수용체 작용제와 함께 데스모프레신을 포함하는 방법 및 조성물
KR20150056443A (ko) * 2013-11-15 2015-05-26 한미약품 주식회사 타다라필 및 암로디핀을 포함하는 복합제제
EP3150201B1 (fr) * 2014-06-30 2020-02-19 Hanmi Pharm. Co., Ltd. Preparation composite comprenant une couche de revêtement pelliculaire contenant un inhibiteur de la 5-alpha-réductase, et procédé pour produire la préparation composite
WO2016003180A1 (fr) * 2014-06-30 2016-01-07 한미약품 주식회사 Preparation composite comprenant une couche de revêtement pelliculaire contenant un inhibiteur de la 5-alpha-réductase, et procédé pour produire la préparation composite
BR112016030731A2 (pt) * 2014-06-30 2017-08-22 Hanmi Pharm Ind Co Ltd Preparação de compósito, e, método de preparação de uma preparação de compósito
KR20240010751A (ko) * 2014-11-20 2024-01-24 세레니티 파마슈티컬즈 엘엘씨 알파-아드레날린성 수용체 길항제와 조합된 데스모프레신을 포함하는 방법 및 조성물
US20190125685A1 (en) * 2016-03-31 2019-05-02 Hanmi Pharm. Co., Ltd. Composite capsule preparation containing tadalafil and tamsulosin and having improved stability and elution rate
KR101835506B1 (ko) * 2016-10-25 2018-03-07 주식회사 에스텍파마 두타스테리드와 타다라필을 함유하는 속효성 복합정제
CN108066347B (zh) * 2016-11-16 2021-02-02 深圳万和制药有限公司 包含坦索罗辛和度他雄胺的口腔崩解片药物组合物
KR101879133B1 (ko) * 2017-07-11 2018-07-17 (주)동구바이오제약 비뇨기 질환 예방 또는 치료용 제제 및 이의 제조방법
TR201715231A2 (tr) * 2017-10-09 2019-04-22 Montero Gida Sanayi Ve Ticaret Anonim Sirketi Dapokseti̇n ve fosfodi̇esteraz ti̇p-5 i̇nhi̇bi̇törü i̇çeren farmasöti̇k kombi̇nasyon

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050042177A1 (en) * 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base

Also Published As

Publication number Publication date
IL186604A0 (en) 2008-01-20
AR053575A1 (es) 2007-05-09
GT200600145A (es) 2007-04-10
MX2007012567A (es) 2007-12-10
EP1888075A1 (fr) 2008-02-20
RU2007141518A (ru) 2009-05-20
MA29683B1 (fr) 2008-08-01
TW200716122A (en) 2007-05-01
DE102005016981A1 (de) 2006-10-19
DOP2006000074A (es) 2006-10-15
SV2008002477A (es) 2008-02-08
AU2006233567A1 (en) 2006-10-19
PE20061338A1 (es) 2007-01-28
BRPI0610634A2 (pt) 2010-07-13
WO2006108519A1 (fr) 2006-10-19
CN101193638A (zh) 2008-06-04
UY29473A1 (es) 2006-11-30
CR9427A (es) 2007-12-17
CA2605224A1 (fr) 2006-10-19
KR20080007252A (ko) 2008-01-17
JP2008535877A (ja) 2008-09-04

Similar Documents

Publication Publication Date Title
TNSN07385A1 (en) Therapeutic combination in case of benign prostate hyperplasia
SG164368A1 (en) Treatment of cancer
WO2007051065A3 (fr) Compositions et traitements destines a inhiber kinase et/ou hmg-coa reductase
MX2009005011A (es) Imidazopirazinas como inhibidores de proteina quinasa.
EA200800441A1 (ru) Замещенные бензимидазолы в качестве ингибиторов киназ
IL229136A0 (en) mek inhibitors and methods of using them
IS7817A (is) Fenýlalanín afleiður sem dípeptidýl peptíðasa hindrar til að meðhöndla eða fyrirbyggja sykursýki.
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
UY29246A1 (es) Nuevos compuestos
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
TW200607525A (en) Compositions for delivering highly water soluble drugs
MX2009003734A (es) Pirazolopirimidinas como inhibidor de cinasas dependientes de ciclina.
MX2007004264A (es) Uso de inhibidores de cinasas jun n-terminales para el tratamiento de retinopat??a glaucomatosa y enfermedades oculares.
WO2006028524A3 (fr) Compositions et traitements pour l'inhibition de kinase et/ou de hmg-coa reductase
WO2007120333A3 (fr) Inhibiteurs de kinase tétracycliques
MXPA05011213A (es) Combinacion de un inhibidor de ciclooxigenasa-2 y un agente antineoplasico tipo alquilacion para tratamiento de neoplasia.
TR200102448T2 (tr) COPD tedavisi için kontrollu salma formülasyonu.
SI1830833T1 (sl) Kombinacija inhibitorja glicinskega transporterja GlyT in antipsihotika za zdravljenje simptomovshizofrenije in tudi njena priprava in njena uporaba
PH12014501454B1 (en) Methods of treating hematologic cancers using pnp inhibitors such as forodesine in combination with alkylating agents or anti-cd20 agents
IL162820A (en) Composition against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors
WO2000074667A3 (fr) Methodes et compositions destinees a la modulation de l'action de medicaments par deterioration de telomeres
WO2004052349A3 (fr) Compositions contenant des inhibiteurs de l'enzyme impdh
UA96742C2 (en) Mek inhibitors and use thereof
JO3254B1 (ar) مثبطات ببتيداز ثنائي ببتيديل لمعالجة مرض السكر